Bortezomib

Specifications

179324-69-7CAS Number

605-854-3EC Number

[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acidIUPAC Name

C19H25BN4O4Chemical Formula

384.2 g/molMolecular Weight

Bortezomib; 179324-69-7; Velcade; PS-341; LDP-341; NSC-681239; DTXSID3040980; LDP 341; Bortezomib accord; 69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; DTXCID1020980; CHEBI:52717; [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; bortezomibum; Bortexomib; LDP341; N-((1R)-1-(DIHYDROXYBORYL)-3-methylbutyl)-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; PS341; ((1R)-3-methyl-1-(((2S)-3-phenyl-2-((pyrazin-2-ylcarbonyl)amino)propanoyl)amino)butyl)boronic acid; [(1R)-3-Methyl-1-[[(2S)-3-phenyl-2-[(pyrazinylcarbonyl)amino]propanoyl]amino]butyl]boronic acid; BORUZU; 341, PS; RefChem:5614; Bortezomib for Injection; L01XX32; ((1R)-3-methyl-1-((2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido)butyl)boronic acid; Bortezomib (PS-341); Ps 341; ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; C19H25BN4O4; MLN-341; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; MFCD09056737; MG-341; Bortezomib (Velcade); PS-341 [Bortezomib]; CHEMBL325041; Peptide boronate; NSC681239; radiciol; NCGC00242506-02; S1013; Pyz-Phe-boroLeu; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid; BORTEZOMIB HYDRATE [JAN]; Velcade (TN); DPBA; CAS-179324-69-7; LPD-341; PS 341 (pharmaceutical); UNII-69G8BD63PP; PROSCRIPT BORONIC ACID; Bortezomib [USAN:INN:BAN]; HSDB 7666; Bortezomib hydrate; Bortezomib,Velcade; LPD 341; NCGC00168751-01; NCGC00181022-01; Bortezomib [USAN]; MG 341; Velcade (Millenium); NSC 681239; Bortezomib (Standard); 3mg0; BORTEZOMIB [MI]; BORTEZOMIB [INN]; BORTEZOMIB [JAN]; 1610526-91-4; BORTEZOMIB [HSDB]; BORTEZOMIB [VANDF]; BORTEZOMIB [MART.]; BORTEZOMIB [WHO-DD]; [(1R)-3-METHYL-1-[[(2S)-1-OXO-3-PHENYL-2-[(PYRAZINYLCARBONYL)AMINO]PROPYL]AMINO]BUTYL]-BORONIC ACID; MLS004774142; Bortezomib (JAN/USAN/INN); BORTEZOMIB [EMA EPAR]; SCHEMBL192129; Bortezomib - Bio-X trade mark; GTPL6391; orb1305542; BORTEZOMIB [ORANGE BOOK]; SCHEMBL29377226; GLXC-05159; EX-A8373; Tox21_112630; Tox21_112672; BDBM50069989; EBC-11290; HB4036; HY-10227R; NSC756655; AKOS015909706; Tox21_112672_1; CCG-268449; DB00188; FM19000; NSC-756655; [(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; NCGC00242506-01; NCGC00242506-06; NCGC00242506-07; NCGC00242506-09; AS-15721; BB164258; HY-10227; NCI60_029010; SMR003500787; SY008095; Bortezomib (Velcade,MG-341,PS-341)?; B5741; NS00006197; SW208077-3; T2399; D03150; EN300-657180; M06307; AB01273951-01; AB01273951-02; AB01273951_03; Q419319; SR-01000939863; SR-01000939863-2; BRD-K88510285-001-02-0; BRD-K88510285-001-11-1; BRD-K88510285-001-17-8; BRD-K88510285-001-18-6; Z2213886907; ((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid; (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid; N-[(1R)-1-Borono-3-methylbutyl]-Nalpha-(pyrazine-2-carbonyl)-L-phenylalaninamide; (1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR; (R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid; Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-; Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-; N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideSynonyms